Is Laurus Labs overvalued or undervalued?

As of 18 July 2025, Laurus Labs' valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios highlight this assessment, with a PE ratio of 124.55, an EV to EBITDA of 44.77, and a Price to Book Value of 9.98, all of which are considerably higher than industry norms. In comparison to its peers, Laurus Labs stands out with a much higher PE ratio than Sun Pharma's 35.49 and Divi's Lab's 81.36, both of which are categorized as expensive or very expensive. Additionally, while companies like Cipla and Dr. Reddy's Labs are rated as attractive with PE ratios of 22.71 and 18.57 respectively, Laurus Labs' elevated ratios suggest it is not justified in its current valuation. Notably, Laurus Labs has outperformed the Sensex with a year-to-date return of 37.32% compared to the Sensex's 4.63%, but this strong performance does not mitigate the overvaluation concern.